Respiri unveils promising wheezo clinical study results
Preliminary results of a clinical study involving the wheezo asthma management platform made by eHealth technology developer Respiri (ASX: RSH) has shown the device is capable of accurately detecting the presence or absence of wheeze in patients with chronic respiratory ailments.
Respiri clinical trial shows ‘substantial agreement’ with doctor stethoscope test for asthma detection
Special Report: Respiri remains on track to commercialise its wheezo™ asthma detection device before the end of the year.
eHealth company Respiri (ASX:RSH) has continued its run of positive news flow, with the release of new clinical trial data this morning.
Respiri catches a screamer with Carlton AFLW deal
Ehealth business Respiri (ASX:RSH) has taken its biggest mark yet for 2021, signing on with the Carlton Football Club’s AFLW team for the upcoming season.
The partnership announcement will see Respiri’s wheezo device and software-as-a-service (SaaS) monitoring system supported by Carlton’s AFLW team to bring awareness of the importance of asthma management to the forefront of the community.
Respiri teams up with Carlton Football Club to promote wheezo device
A day after publishing its full year accounts, eHealth company Respiri (ASX: RSH) has tentatively set foot in Australian rules football courtesy of a partnership with Carlton Football Club AFLW, commencing from next season.
Respiri signs referral agreement with APA to proliferate wheezo in Australia
eHealth company Respiri (ASX: RSH) has taken another step towards growing sales of its wheezo device ahead of its October launch, after signing a three-year product referral agreement (PRA) with the Australian Patients Association (APA).
StockTalk: How are ASX medtechs responding to skyrocketing healthcare spending?
StockTalk is a Stockhead video series featuring a roundtable of experts discussing a new investment topic each week. In this edition, host Dr Nigel Finch discusses skyrocketing healthcare spending and its impact on the medtech sub-sector.
Respiri, APA partner to give 1.1m patients access to wheezo study
Special Report: Respiri (ASX:RSH) has won over the Australian Patients Association (APA) for its wheezo Experiential Program, a real-world asthma management study designed to support people living with the condition.
Respiri partners with Australian Patients Association for wheezo study
eHealth Software-as-a-Service (Saas) company Respiri (ASX: RSH) has updated the market with news it has entered into a partnership with the Australian Patients Association (APA) to support asthma sufferers through its wheezo experiential program – a real-world asthma management study.
Respiri eyes maiden 2021 revenue of $6-8m
Special Report: Respiri is changing gears from development company to fledged revenue-generating medtech business.
Respiri (ASX:RSH) expects revenue to be in the millions in 2021, after accelerating to a maiden full year revenue figure of $6m-8m. The eHealth Software as a Service (SaaS) company has spent the last six months signing commercial deals and outreach programs to sell its respiratory health management wheezo device and SaaS subscriptions.
eHealth SaaS provider Respiri targets $6-8m revenue for 2021
eHealth technology developer and maker of the wheezo device, Respiri (ASX: RSH) has published interim revenue guidance for 2021 with total revenues from both device and software subscription estimated to reach $6-$8 million.
JOIN OUR NEWSLETTER
Be the first to hear of Respiri’s latest news and subscribe to the bi-monthly newsletter here.